Amylin Pharmaceuticals (AMLN) To Launch Diabetes Drug

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is preparing to launch a once-weekly version of its exenatide diabetes drug later this year.

Daniel M. Bradbury, CEO of Amylin Pharmaceuticals, said that regulators have not requested additional data. The share price of the company was $15.77. Mr Bradbury said that the corporate priority this year is to address the dual epidemics of diabetes and obesity, achieve positive operating cash flow by the end of the year and place the Company on the path to operating profitability by the end of 2011.